我的最终目标是将从PubMed接收的元数据加载到pyspark数据帧中。到目前为止，我已经设法使用Shell脚本从PubMed数据库下载所需的数据。下载的数据为asn1格式。这是数据输入的示例：
Pubmed-entry ::= {
pmid 31782536,
medent {
em std {
year 2019,
month 11,
day 30,
hour 6,
minute 0
},
cit {
title {
name "Impact of CYP2C19 genotype and drug interactions on voriconazole
plasma concentrations: a spain pharmacogenetic-pharmacokinetic prospective
multicenter study."
},
authors {
names std {
{
name ml "Blanco Dorado S",
affil str "Pharmacy Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain.; Clinical
Pharmacology Group, University Clinical Hospital, Health Research Institute
of Santiago de Compostela (IDIS). Santiago de Compostela, Spain.; Department
of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy,
University of Santiago de Compostela (USC). Santiago de Compostela, Spain."
},
{
name ml "Maronas O",
affil str "Genomic Medicine Group, Centro Nacional de Genotipado
(CEGEN-PRB3), CIBERER, CIMUS, University of Santiago de Compostela (USC),
Santiago de Compostela, Spain."
},
{
name ml "Latorre-Pellicer A",
affil str "Genomic Medicine Group, Centro Nacional de Genotipado
(CEGEN-PRB3), CIBERER, CIMUS, University of Santiago de Compostela (USC),
Santiago de Compostela, Spain."
},
{
name ml "Rodriguez Jato T",
affil str "Pharmacy Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain."
},
{
name ml "Lopez-Vizcaino A",
affil str "Pharmacy Department, University Hospital Lucus Augusti
(HULA). Lugo, Spain."
},
{
name ml "Gomez Marquez A",
affil str "Pharmacy Department, University Hospital Ourense
(CHUO). Ourense, Spain."
},
{
name ml "Bardan Garcia B",
affil str "Pharmacy Department, University Hospital Ferrol (CHUF).
A Coruna, Spain."
},
{
name ml "Belles Medall D",
affil str "Pharmacy Department, General University Hospital
Castellon (GVA). Castellon, Spain."
},
{
name ml "Barbeito Castineiras G",
affil str "Microbiology Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain."
},
{
name ml "Perez Del Molino Bernal ML",
affil str "Microbiology Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain."
},
{
name ml "Campos-Toimil M",
affil str "Department of Pharmacology, Pharmacy and Pharmaceutical
Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC).
Santiago de Compostela, Spain."
},
{
name ml "Otero Espinar F",
affil str "Department of Pharmacology, Pharmacy and Pharmaceutical
Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC).
Santiago de Compostela, Spain."
},
{
name ml "Blanco Hortas A",
affil str "Epidemiology Unit. Fundacion Instituto de Investigacion
Sanitaria de Santiago de Compostela (FIDIS), University Hospital Lucus
Augusti (HULA), Spain."
},
{
name ml "Duran Pineiro G",
affil str "Clinical Pharmacology Group, University Clinical
Hospital, Health Research Institute of Santiago de Compostela (IDIS).
Santiago de Compostela, Spain."
},
{
name ml "Zarra Ferro I",
affil str "Pharmacy Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain.; Clinical
Pharmacology Group, University Clinical Hospital, Health Research Institute
of Santiago de Compostela (IDIS). Santiago de Compostela, Spain."
},
{
name ml "Carracedo A",
affil str "Genomic Medicine Group, Centro Nacional de Genotipado
(CEGEN-PRB3), CIBERER, CIMUS, University of Santiago de Compostela (USC),
Santiago de Compostela, Spain.; Galician Foundation of Genomic Medicine,
Health Research Institute of Santiago de Compostela (IDIS), SERGAS, Santiago
de Compostela, Spain."
},
{
name ml "Lamas MJ",
affil str "Clinical Pharmacology Group, University Clinical
Hospital, Health Research Institute of Santiago de Compostela (IDIS).
Santiago de Compostela, Spain."
},
{
name ml "Fernandez-Ferreiro A",
affil str "Pharmacy Department, University Clinical Hospital
Santiago de Compostela (CHUS). Santiago de Compostela, Spain.; Clinical
Pharmacology Group, University Clinical Hospital, Health Research Institute
of Santiago de Compostela (IDIS). Santiago de Compostela, Spain.; Department
of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy,
University of Santiago de Compostela (USC). Santiago de Compostela, Spain."
}
}
},
from journal {
title {
iso-jta "Pharmacotherapy",
ml-jta "Pharmacotherapy",
issn "1875-9114",
name "Pharmacotherapy"
},
imp {
date std {
year 2019,
month 11,
day 29
},
language "eng",
pubstatus aheadofprint,
history {
{
pubstatus other,
date std {
year 2019,
month 11,
day 30,
hour 6,
minute 0
}
},
{
pubstatus pubmed,
date std {
year 2019,
month 11,
day 30,
hour 6,
minute 0
}
},
{
pubstatus medline,
date std {
year 2019,
month 11,
day 30,
hour 6,
minute 0
}
}
}
}
},
ids {
pubmed 31782536,
doi "10.1002/phar.2351",
other {
db "ELocationID doi",
tag str "10.1002/phar.2351"
}
}
},
abstract "BACKGROUND: Voriconazole, a first-line agent for the treatment
of invasive fungal infections, is mainly metabolized by cytochrome P450 (CYP)
2C19. A significant portion of patients fail to achieve therapeutic
voriconazole trough concentrations, with a consequently increased risk of
therapeutic failure. OBJECTIVE: To show the association between
subtherapeutic voriconazole concentrations and factors affecting voriconazole
pharmacokinetics: CYP2C19 genotype and drug-drug interactions. METHODS:
Adults receiving voriconazole for antifungal treatment or prophylaxis were
included in a multicenter prospective study conducted in Spain. The
prevalence of subtherapeutic voriconazole troughs were analyzed in the rapid
metabolizer and ultra-rapid metabolizer patients (RMs and UMs, respectively),
and compared with the rest of the patients. The relationship between
voriconazole concentration, CYP2C19 phenotype, adverse events (AEs), and
drug-drug interactions was also assessed. RESULTS: In this study 78 patients
were included with a wide variability in voriconazole plasma levels with only
44.8% of patients attaining trough concentrations within the therapeutic
range of 1 and 5.5 microg/ml. The allele frequency of *17 variant was found
to be 29.5%. Compared with patients with other phenotypes, RMs and UMs had a
lower voriconazole plasma concentration (RM/UM: 1.85+/-0.24 microg/ml versus
other phenotypes: 2.36+/-0.26 microg/ml, ). Adverse events were more common
in patients with higher voriconazole concentrations (p<0.05). No association
between voriconazole trough concentration and other factors (age, weight,
route of administration, and concomitant administration of enzyme inducer,
enzyme inhibitor, glucocorticoids, or proton pump inhibitors) was found.
CONCLUSION: These results suggest the potential clinical utility of using
CYP2C19 genotype-guided voriconazole dosing to achieve concentrations in the
therapeutic range in the early course of therapy. Larger studies are needed
to confirm the impact of pharmacogenetics on voriconazole pharmacokinetics.",
pmid 31782536,
pub-type {
"Journal Article"
},
status publisher
}
}
这就是我被困住的地方。我不知道如何从asn1中提取信息并将其放入pyspark数据帧中。有人可以建议这样做的方法吗？
您的问题可能并不简单，但是值得尝试。
方法1：
按照您的说明，您可以尝试寻找将创建数据模型的ASN.1工具（也称为ASN.1编译器）。就您而言，因为您下载了文本ASN.1值，所以需要此工具来提供ASN.1值解码器。
如果该工具正在生成Java代码，它将像这样：
// decode a Pubmed-entry
// input is your data
Asn1ValueReader reader = new Asn1ValueReader(input);
PubmedEntry obj = PubmedEntry.readPdu(reader);
// access the data
obj.getPmid();
obj.getMedent();
一些警告：
我之前写过this，但没有文本的ASN1值解码器
方法2：
如果您的数据足够简单，并且它们是文本数据，则可以尝试编写自己的解析器（使用ANTLR之类的工具。。。如果不熟悉解析器，则不容易评估此方法。
编辑：不幸的是，specification无效。